The news today creates a 2nd deal to combine CLRX knowledge base with molecular tests. Other molecular diagnostic companies will have to follow over time to keep pace and compete with alternative tests. Physicians and other healthcare service provides need and want actionable intelligence. They get test results, now what? What drugs do you prescribe? What clinical trials do we get you into? Do we need to run other tests? The volume of data that is being generated post the cracking of the Human Genome is enormous. Physicians and other point of care service providers have VERY LITTLE TIME and DON'T READ ENOUGH (medical journals) to know exactly what to do. With CLRX's information coupled with the tests, they will know the options.
This is a paradigm shift in care. If you are short and don't see that, good luck to you. If you have yet to buy this stock, ignore all the mumble jumble about TGAL (which did lose shareholders a lot of money), and focus on CLRX and the deals that have been struck. Go to the CLRX website and read up on the technology, the editorial group, and the network of physicians and researchers being amassed to aggregate and organize the genetic cancer data. It is an extremely impressive group.
On the last conference call, the CEO stated that one more deal like LIFE this year would help CLRX break-even....which is quite an accomplishment for a young firm. The real ramp in revenue will take place over time as molecular tests are rolled out with the CLRX knowledge base. There a millions of genetic tests worldwide.
CLRX market cap is now about $3 million, net of cash. This will be a 100-bagger. Today's volume a great indicator that old TGAL shareholders ,who didn't get out on the LIFE Technologies partnership, are throwing in the towel. This is GREAT for CLRX shareholders...a new shareholder base is exactly what the doctor ordered. Buy all pullbacks and load up the boat!
Thanks for the post well done. The big shift is happening and its only inning one. Massive data needs to be consolidated for point of care pros to assess and use quickly. CLRX is essentially first to market. LIFE realized this and now others joining. Deal flow should come quickly. As cost of genetic testing drops , the need becomes more real. Again please go listen to cc if you have not. Cash flow breakeven is near. More importantly , have nice nol to use against future earns for some time. Good luck to you.